MRNA stock forecast
Our latest prediction for Moderna, Inc.'s stock price was made on the Aug. 3, 2020 when the stock price was at 77.98$.
In the short term (2weeks), MRNA's stock price should underperform the market by -2.10%. During that period the price should oscillate between -10.58% and +8.95%.
In the medium term (3months), MRNA's stock price should underperform the market by -7.34%. During that period the price should oscillate between -36.59% and +20.43%.Get email alerts
Create a solid portfolio with MRNA
About Moderna, Inc.
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
At the moment the company generates 53M USD in revenues.
On its last earning announcement, the company reported a loss of -1.50$ per share.
The book value per share is 4.05$
Three months stock forecastAug. 3, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|